Mumbai, July 21 -- Profit before tax (PBT) rose 16.2% YoY to Rs 51.11 crore in Q1 June 2025.

EBITDA jumped 12% to Rs 74.4 crore in Q1 FY26 compared with Rs 66.1 crore in Q1 FY25. EBITDA margin expanded by 70 bps to 12.6% in Q1 FY26 from 11.9% posted in Q1 FY25.

On segmental front, the revenue from API stood at Rs 458.2 crore (up 4% YoY), formulations was at Rs 80.3 crore (up 14% YoY), specialty & chemicals stood at Rs 33.1 crore (up 24% YoY) and intermediaries & others stood at Rs 18.9 crore (up 22% YoY) during the period under review.

Adhish Patil, CFO & COO, of Aarti Drugs, said, "During Q1FY26 the Company incurred Capex of

Published by HT Digital Content Services with permission from Capital Market....